Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs
Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, s...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a6c489c2bcc54f038b6446d5f3f4da1e | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Alessandra Romandini |e author |
| 700 | 1 | 0 | |a Damiano Baldassarre |e author |
| 700 | 1 | 0 | |a Stefano Genovese |e author |
| 700 | 1 | 0 | |a Stefano Capri |e author |
| 700 | 1 | 0 | |a Giulio Pompilio |e author |
| 700 | 1 | 0 | |a Marco Scatigna |e author |
| 700 | 1 | 0 | |a José Pablo Werba |e author |
| 245 | 0 | 0 | |a Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs |
| 260 | |b MDPI AG, |c 2023-01-01T00:00:00Z. | ||
| 500 | |a 10.3390/ph16020176 | ||
| 500 | |a 1424-8247 | ||
| 520 | |a Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered "unmodifiable". The present paper is a viewpoint aimed at presenting the incremental metabolic and cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their prescription by physicians and their assumption by patients, which need to be worked out for a more diffuse and appropriate drug utilization. | ||
| 546 | |a EN | ||
| 690 | |a atherogenic dyslipidemia | ||
| 690 | |a lipid-modifying drugs | ||
| 690 | |a cardiovascular disease | ||
| 690 | |a drug intolerance | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceuticals, Vol 16, Iss 2, p 176 (2023) | |
| 787 | 0 | |n https://www.mdpi.com/1424-8247/16/2/176 | |
| 787 | 0 | |n https://doaj.org/toc/1424-8247 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a6c489c2bcc54f038b6446d5f3f4da1e |z Connect to this object online. |